Join the club for FREE to access the whole archive and other member benefits.

Jerry McLaughlin

Chief Executive Officer at Life Biosciences

Jerry McLaughlin is chief executive officer and board member of Life Biosciences, Inc. He has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, he served as president and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of senior vice president & chief commercial officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches.

He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.

Visit website:


See also: Company Life Biosciences - Drug development company promoting longevity and finding treatments for age-related diseases

Details last updated 14-Mar-2022

Jerry McLaughlin is also referenced in the following:

Age-Related Disease Therapeutics Summit

31-May-2023 to 02-Jun-2023

Event about aging and aging related diseases organized by Hanson Wade

ARDD 2023 - 10th Aging Research & Drug Discovery Meeting

28-Aug-2023 to 01-Sep-2023

Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen

Global Healthspan Summit 2023

29-Nov-2023 to 30-Nov-2023

Longevity summit organised by Hevolution Foundation (Riyadh,Saudi Arabia)

Jerry McLaughlin News

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years


Life Biosciences raises funding to develop innovative therapies against ageing biology

Longevity Technology - 06-Jan-2022

Invests $82 million in research platforms, aiming to prevent or reverse age-related diseases